Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling

Cancer Chemother Pharmacol. 1992;30(2):149-51. doi: 10.1007/BF00686408.

Abstract

A "priming" injection of cyclophosphamide (400 mg/m2 given i.v. on day -7) has been shown to reduce intestinal permeability and thus gut toxicity in patients receiving high-dose melphalan. To determine the optimal timing for this injection, patients receiving 200 mg/m2 melphalan with an autologous bone marrow transplant were randomly assigned to receive cyclophosphamide at 5, 7 or 9 days before the melphalan. The median percentage of [51Cr]-ethylenediaminetetraacetic acid excretion was similar (9.1% vs 7.1% vs 7.7%, respectively), with equivalent duration of WHO grade 2-4 mucositis and diarrhoea being recorded for each group. Thus, the timing of the cyclophosphamide prime is not critical, and the priming injection may be given between 5 and 9 days prior to high-dose melphalan.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow Transplantation
  • Chromium Radioisotopes
  • Combined Modality Therapy
  • Cyclophosphamide / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Edetic Acid / pharmacokinetics
  • Gastrointestinal Diseases / chemically induced
  • Gastrointestinal Diseases / prevention & control*
  • Humans
  • Melphalan / administration & dosage*
  • Melphalan / adverse effects
  • Melphalan / therapeutic use
  • Neoplasms / drug therapy*
  • Neoplasms / surgery

Substances

  • Chromium Radioisotopes
  • Cyclophosphamide
  • Edetic Acid
  • Melphalan